Clinical Trials : Prurigo

Completed

Study Name: Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease
Condition: Prurigo Nodularis
Date: 2007-07-26
Interventions:

Drug: Pimecrolimus twice daily

Completed

Study Name: Topical Aprepitant in Prurigo Patients
Condition: Pruritus
Date: 2013-09-18
Interventions:

Drug: Aprepitant Aprepitant ge

Completed

Study Name: A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Condition: Prurigo
Date: 2025-12-15
Interventions: Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).

Completed

Study Name: A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Condition: Prurigo Nodularis
Date: 2025-12-15
Interventions: Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.

COMPLETED

Study Name: A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
Condition: Prurigo Nodularis
Date: 2025-12-15
Interventions: Ruxolitinib Cream 1.5%

COMPLETED

Study Name: A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Condition: Prurigo Nodularis
Date: 2025-12-15
Interventions: Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.

Search for Clinical Trial Results

Prurigo - 6 Studies Found

Status	Study
Completed	Study Name: Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Condition: Prurigo Nodularis Date: 2007-07-26 Interventions: Drug: Pimecrolimus twice daily
Completed	Study Name: Topical Aprepitant in Prurigo Patients Condition: Pruritus Date: 2013-09-18 Interventions: Drug: Aprepitant Aprepitant ge
Completed	Study Name: A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Condition: Prurigo Date: 2025-12-15 Interventions: Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).
Completed	Study Name: A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Condition: Prurigo Nodularis Date: 2025-12-15 Interventions: Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
COMPLETED	Study Name: A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream Condition: Prurigo Nodularis Date: 2025-12-15 Interventions: Ruxolitinib Cream 1.5%
COMPLETED	Study Name: A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Condition: Prurigo Nodularis Date: 2025-12-15 Interventions: Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.